Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4⁺ T cells
J. Clin. Invest. Daphne C. Tsitoura, et al. 113:619 doi:10.1172/JCI18975 [Go to this article.]

Figure 5
Dex treatment does not affect ERK and JNK activation. Cell extracts were prepared from Dex-treated and control naive CD4+ T cells stimulated with anti-CD3, anti-CD3 plus IL-2, or anti-CD3 plus anti-CD28. The phosphorylation of (a) ERK and (b) JNK was assessed by Western blotting using specific Ab’s. Results from a representative experiment are shown.